Opko Health (NASDAQ:OPK) Downgraded by ValuEngine

ValuEngine cut shares of Opko Health (NASDAQ:OPK) from a buy rating to a hold rating in a report released on Thursday morning, ValuEngine reports.

A number of other brokerages have also weighed in on OPK. Barrington Research restated a buy rating and set a $4.00 price objective on shares of Opko Health in a research report on Thursday, May 7th. BidaskClub lowered Opko Health from a buy rating to a hold rating in a research report on Wednesday, May 27th. Finally, Piper Sandler boosted their price objective on Opko Health from $3.00 to $4.00 in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $3.13.

Opko Health stock opened at $3.54 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.12 and a quick ratio of 0.88. Opko Health has a 52 week low of $1.12 and a 52 week high of $4.04. The stock has a fifty day moving average of $2.60 and a 200-day moving average of $1.89.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). The company had revenue of $211.50 million during the quarter, compared to analysts’ expectations of $215.93 million. Opko Health had a negative return on equity of 13.56% and a negative net margin of 32.92%. On average, sell-side analysts anticipate that Opko Health will post -0.3 earnings per share for the current fiscal year.

In related news, CEO Phillip Md Et Al Frost purchased 200,000 shares of Opko Health stock in a transaction on Wednesday, April 15th. The shares were purchased at an average price of $1.55 per share, for a total transaction of $310,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $4,756,874.05. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders acquired a total of 1,775,000 shares of company stock worth $3,156,500 in the last quarter. Corporate insiders own 40.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in OPK. State Street Corp raised its stake in Opko Health by 3.0% during the 1st quarter. State Street Corp now owns 18,440,431 shares of the biotechnology company’s stock worth $24,710,000 after buying an additional 542,095 shares during the period. Royal Bank of Canada raised its stake in Opko Health by 14.2% during the 1st quarter. Royal Bank of Canada now owns 207,763 shares of the biotechnology company’s stock worth $277,000 after buying an additional 25,840 shares during the period. HighTower Advisors LLC acquired a new position in Opko Health during the 1st quarter worth approximately $30,000. Advisor Group Holdings Inc. acquired a new position in Opko Health during the 1st quarter worth approximately $223,000. Finally, Oracle Investment Management Inc. raised its stake in Opko Health by 2.3% during the 1st quarter. Oracle Investment Management Inc. now owns 4,473,076 shares of the biotechnology company’s stock worth $5,994,000 after buying an additional 100,000 shares during the period. Institutional investors own 23.68% of the company’s stock.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Recommended Story: Dividend Yield

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.